Uveal Melanoma

  • Richard L. S. JennelleEmail author
  • Jesse L. Berry
  • Jonathan W. Kim


In this chapter we review the current state of the art for uveal melanoma. Diagnosis, prognosis, and disease management are reviewed with special attention to the latest developments in molecular genetics. We also review the many eye conserving options for treatment of this disease with a special focus on advanced episcleral plaque brachytherapy. Modern therapeutic advances have now reached a point that nearly all eyes can be managed in a conservative manner with significant visual preservation for most patients.


Uveal melanoma Choroidal melanoma Episcleral plaque Brachytherapy Stereotactic radiation Charged particle therapy Transpupillary thermotherapy Trans-scleral local resection 


  1. 1.
    Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin N Am. 2005;18(1):75–84. viiiGoogle Scholar
  2. 2.
    Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239–51.Google Scholar
  3. 3.
    Weis E, Salopek TG, McKinnon JG, et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol. 2016;23(1):e57–64.Google Scholar
  4. 4.
    Gallagher RP, Elwood JM, Rootman J, et al. Risk factors for ocular melanoma: Western Canada Melanoma Study. J Natl Cancer Inst. 1985;74(4):775–8.Google Scholar
  5. 5.
    Zloto O, Pe'er J, Frenkel S. Gender differences in clinical presentation and prognosis of uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(1):652–6.Google Scholar
  6. 6.
    Weis E, Shah CP, Lajous M, et al. The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis. Ophthalmology. 2009;116(3):536–43.e2.Google Scholar
  7. 7.
    Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005;112(10):1784–9.Google Scholar
  8. 8.
    Yanoff M, Zimmerman LE. Histogenesis of malignant melanomas of the uvea. II. Relationship of uveal nevi to malignant melanomas. Cancer. 1967;20(4):493–507.Google Scholar
  9. 9.
    Guenel P, Laforest L, Cyr D, et al. Occupational risk factors, ultraviolet radiation, and ocular melanoma: a case-control study in France. Cancer Causes Control. 2001;12(5):451–9.Google Scholar
  10. 10.
    Holly EA, Aston DA, Char DH, et al. Uveal melanoma in relation to ultraviolet light exposure and host factors. Cancer Res. 1990;50(18):5773–7.Google Scholar
  11. 11.
    Seddon JM, Gragoudas ES, Glynn RJ, et al. Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol. 1990;108(9):1274–80.Google Scholar
  12. 12.
    Lynch HT, Anderson DE, Krush AJ. Heredity and intraocular malignant melanoma. Study of two families and review of forty-five cases. Cancer. 1968;21(1):119–25.Google Scholar
  13. 13.
    Lynch HT, Krush AJ. Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J. 1968;99(1):17–21.Google Scholar
  14. 14.
    Walker JP, Weiter JJ, Albert DM, et al. Uveal malignant melanoma in three generations of the same family. Am J Ophthalmol. 1979;88(4):723–6.Google Scholar
  15. 15.
    Greene MH, Sanders RJ, Chu FC, et al. The familial occurrence of cutaneous melanoma, intraocular melanoma, and the dysplastic nevus syndrome. Am J Ophthalmol. 1983;96(2):238–45.Google Scholar
  16. 16.
    Vink J, Crijns MB, Mooy CM, et al. Ocular melanoma in families with dysplastic nevus syndrome. J Am Acad Dermatol. 1990;23(5 Pt 1):858–62.Google Scholar
  17. 17.
    Singh AD, Wang MX, Donoso LA, et al. Genetic aspects of uveal melanoma: a brief review. Semin Oncol. 1996;23(6):768–72.Google Scholar
  18. 18.
    Bacin F, Kemeny JL, D’Hermies F, et al. Malignant melanoma of the choroid associated with neurofibromatosis. J Fr Ophtalmol. 1993;16(3):184–90.Google Scholar
  19. 19.
    Wiznia RA, Freedman JK, Mancini AD, et al. Malignant melanoma of the choroid in neurofibromatosis. Am J Ophthalmol. 1978;86(5):684–7.Google Scholar
  20. 20.
    Yanoff M, Zimmerman LE. Histogenesis of malignant melanomas of the uvea. 3. The relationship of congenital ocular melanocytosis and neurofibromatosis in uveal melanomas. Arch Ophthalmol. 1967;77(3):331–6.Google Scholar
  21. 21.
    Rai K, Pilarski R, Boru G, et al. Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 2017;56(2):168–74.Google Scholar
  22. 22.
    Decatur CL, Ong E, Garg N, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.Google Scholar
  23. 23.
    Velazquez N, Jones IS. Ocular and oculodermal melanocytosis associated with uveal melanoma. Ophthalmology. 1983;90(12):1472–6.Google Scholar
  24. 24.
    Carreno E, Saornil MA, Garcia-Alvarez C, et al. Prevalence of ocular and oculodermal melanocytosis in Spanish population with uveal melanoma. Eye (Lond). 2012;26(1):159–62.Google Scholar
  25. 25.
    Shields CL, Kaliki S, Livesey M, et al. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013;131(8):993–1003.Google Scholar
  26. 26.
    Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127(8):981–7.Google Scholar
  27. 27.
    Kivela T. Diagnosis of uveal melanoma. Dev Ophthalmol. 2012;49:1–15.Google Scholar
  28. 28.
    Tarlan B, Kiratli H. Uveal melanoma: current trends in diagnosis and management. Turk J Ophthalmol. 2016;46(3):123–37.Google Scholar
  29. 29.
    Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol. 1997;115(12):1537–1544.Google Scholar
  30. 30.
    Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol. 1990;108(9):1268–1273.Google Scholar
  31. 31.
    Margo CE. The accuracy of diagnosis of posterior uveal melanoma. Arch Ophthalmol. 1997;115(3):432–4.Google Scholar
  32. 32.
    Kielar RA. Choroidal melanoma appearing as vitreous hemorrhage. Ann Ophthalmol. 1982;14(5):461–4.Google Scholar
  33. 33.
    Skalka HW. Choroidal hemorrhage simulating malignant melanoma. J Clin Ultrasound. 1982;10(4):190–2.Google Scholar
  34. 34.
    Fraser DJ Jr, Font RL. Ocular inflammation and hemorrhage as initial manifestations of uveal malignant melanoma. Incidence and prognosis. Arch Ophthalmol. 1979;97(7):1311–4.Google Scholar
  35. 35.
    Giuliari GP, Connor A, Simpson ER. Amelanotic choroidal melanoma. Lancet. 2011;377(9768):848.Google Scholar
  36. 36.
    Lee DS, Anderson SF, Perez EM, et al. Amelanotic choroidal nevus and melanoma: cytology, tumor size, and pigmentation as prognostic indicators. Optom Vis Sci. 2001;78(7):483–91.Google Scholar
  37. 37.
    Gibran SK, Kapoor KG. Management of exudative retinal detachment in choroidal melanoma. Clin Exp Ophthalmol. 2009;37(7):654–9.Google Scholar
  38. 38.
    Harbour JW, Ahmad S, El-Bash M. Rate of resolution of exudative retinal detachment after plaque radiotherapy for uveal melanoma. Arch Ophthalmol. 2002;120(11):1463–9.Google Scholar
  39. 39.
    Kivela T, Eskelin S, Makitie T, et al. Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol Vis Sci. 2001;42(9):2085–93.Google Scholar
  40. 40.
    Collaborative Ocular Melanoma Study G, Boldt HC, Byrne SF, et al. Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report no. 29. Ophthalmology. 2008;115(8):1390–7. 7.e1–2Google Scholar
  41. 41.
    Collaborative Ocular Melanoma Study G. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS report no. 21. Arch Ophthalmol. 2003;121(8):1163–71.Google Scholar
  42. 42.
    Margo CE. The collaborative ocular melanoma study: an overview. Cancer Control. 2004;11(5):304–9.Google Scholar
  43. 43.
    Amin MB, Edge SB, Cancer. AJCo. AJCC cancer staging manual 2017. 2017.Google Scholar
  44. 44.
    Augsburger JJ, Correa ZM, Schneider S, et al. Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category. Trans Am Ophthalmol Soc. 2002;100:225–32. discussion 32–4Google Scholar
  45. 45.
    Singh AD, Medina CA, Singh N, et al. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016;100(4):456–62.Google Scholar
  46. 46.
    De Croock L, Verbraeken H. Metastatic uveal melanoma: diagnosis and treatment. A literature review. Bull Soc Belge Ophtalmol. 2002;286:59–63.Google Scholar
  47. 47.
    Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010;128(7):871–5.Google Scholar
  48. 48.
    Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123(12):1639–43.Google Scholar
  49. 49.
    Shields JA, Augsburger JJ, Brown GC, et al. The differential diagnosis of posterior uveal melanoma. Ophthalmology. 1980;87(6):518–22.Google Scholar
  50. 50.
    Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998;125(6):745–766.Google Scholar
  51. 51.
    Coleman K, Baak JP, van Diest PJ, et al. Prognostic value of morphometric features and the Callender classification in uveal melanomas. Ophthalmology. 1996;103(10):1634–41.Google Scholar
  52. 52.
    Collaborative Ocular Melanoma Study G. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119(5):670–6.Google Scholar
  53. 53.
    McLean IW, Ainbinder DJ, Gamel JW, et al. Choroidal-ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology. 1995;102(7):1060–4.Google Scholar
  54. 54.
    Damato BE, Heimann H, Kalirai H, et al. Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival. JAMA Ophthalmol. 2014;132(5):605–13.Google Scholar
  55. 55.
    Collaborative Ocular Melanoma Study G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684–93.Google Scholar
  56. 56.
    Mortality in patients with small choroidal melanoma. COMS report no. 4. The collaborative ocular melanoma study group. Arch Ophthalmol. 1997;115(7):886–893.Google Scholar
  57. 57.
    The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998;125(6):779–796.Google Scholar
  58. 58.
    Correa ZM. Assessing prognosis in uveal melanoma. Cancer Control. 2016;23(2):93–8.Google Scholar
  59. 59.
    Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.Google Scholar
  60. 60.
    Dopierala J, Damato BE, Lake SL, et al. Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest Ophthalmol Vis Sci. 2010;51(10):4898–905.Google Scholar
  61. 61.
    Singh AD, Donoso LA. Genetic aspects of uveal melanoma. Int Ophthalmol Clin. 1993;33(3):47–52.Google Scholar
  62. 62.
    Singh AD, Boghosian-Sell L, Wary KK, et al. Cytogenetic findings in primary uveal melanoma. Cancer Genet Cytogenet. 1994;72(2):109–15.Google Scholar
  63. 63.
    Singh AD. Prognostication of uveal melanoma: a work in progress. JAMA Ophthalmol. 2016;134(7):740–1.Google Scholar
  64. 64.
    Kilic E, van Gils W, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci. 2006;47(9):3703–7.Google Scholar
  65. 65.
    Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234–9.Google Scholar
  66. 66.
    Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol. 2014;1102:427–40.Google Scholar
  67. 67.
    Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109(12):2197–206.Google Scholar
  68. 68.
    Marucci L, Ancukiewicz M, Lane AM, et al. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys. 2011;79(3):842–6.Google Scholar
  69. 69.
    Ophthalmic Oncology Task F. Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology. 2016;123(1):86–91.Google Scholar
  70. 70.
    Foulds WS, Damato BE, Burton RL. Local resection versus enucleation in the management of choroidal melanoma. Eye. 1987;1(Pt 6):676–9.Google Scholar
  71. 71.
    Damato B, Foulds WS. Indications for trans-scleral local resection of uveal melanoma. Br J Ophthalmol. 1996;80(11):1029–30.Google Scholar
  72. 72.
    Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol. 1996;80(2):102–8.Google Scholar
  73. 73.
    Damato BE. Local resection of uveal melanoma. Dev Ophthalmol. 2012;49:66–80.Google Scholar
  74. 74.
    Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, et al. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol. 1995;113(3):315–21.Google Scholar
  75. 75.
    Journee-de Korver JG, Oosterhuis JA, Kakebeeke-Kemme HM, et al. Transpupillary thermotherapy (TTT) by infrared irradiation of choroidal melanoma. Doc Ophthalmol. 1992;82(3):185–91.Google Scholar
  76. 76.
    Journee-de Korver JG, Oosterhuis JA, de Wolff-Rouendaal D, et al. Histopathological findings in human choroidal melanomas after transpupillary thermotherapy. Br J Ophthalmol. 1997;81(3):234–9.Google Scholar
  77. 77.
    Shields CL, Shields JA, DePotter P, et al. Transpupillary thermotherapy in the management of choroidal melanoma. Ophthalmology. 1996;103(10):1642–50.Google Scholar
  78. 78.
    Shields CL, Shields JA, Cater J, et al. Transpupillary thermotherapy for choroidal melanoma: tumor control and visual results in 100 consecutive cases. Ophthalmology. 1998;105(4):581–90.Google Scholar
  79. 79.
    Kashani AH, Aaberg TM Jr, Capone A Jr. Vitreomacular traction as a consequence of posterior hyaloidal contraction after transpupillary thermotherapy. Am J Ophthalmol. 2013;155(5):937–45.Google Scholar
  80. 80.
    Shields CL, Shields JA. Transpupillary thermotherapy for choroidal melanoma. Curr Opin Ophthalmol. 1999;10(3):197–203.Google Scholar
  81. 81.
    Aaberg TM Jr, Bergstrom CS, Hickner ZJ, et al. Long-term results of primary transpupillary thermal therapy for the treatment of choroidal malignant melanoma. Br J Ophthalmol. 2008;92(6):741–6.Google Scholar
  82. 82.
    Win PH, Robertson DM, Buettner H, et al. Extended follow-up of small melanocytic choroidal tumors treated with transpupillary thermotherapy. Arch Ophthalmol. 2006;124(4):503–6.Google Scholar
  83. 83.
    Shields CL, Cater J, Shields JA, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol. 2002;120(7):933–40.Google Scholar
  84. 84.
    Bartlema YM, Oosterhuis JA, Journee-De Korver JG, et al. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years’ experience. Br J Ophthalmol. 2003;87(11):1370–3.Google Scholar
  85. 85.
    Oosterhuis JA, Journee-de Korver HG, Keunen JE. Transpupillary thermotherapy: results in 50 patients with choroidal melanoma. Arch Ophthalmol. 1998;116(2):157–62.Google Scholar
  86. 86.
    De Potter P, Jamart J. Adjuvant indocyanine green in transpupillary thermotherapy for choroidal melanoma. Ophthalmology. 2003;110(2):406–13. discussion 13–4Google Scholar
  87. 87.
    Stallard HB. Malignant melanoma of the choroid treated with radioactive applicators: Hunterian lecture delivered at the Royal College of Surgeons of England on 29th November 1960. Ann R Coll Surg Engl. 1961;29:170–82.Google Scholar
  88. 88.
    Augsburger JJ, Gamel JW, Lauritzen K, et al. Cobalt-60 plaque radiotherapy vs enucleation for posterior uveal melanoma. Am J Ophthalmol. 1990;109:585–92.Google Scholar
  89. 89.
    Earle J, Kline RW, Robertson DM. Selection of iodine 125 for the Collaborative Ocular Melanoma Study. Arch Ophthalmol. 1987;105:763–4.Google Scholar
  90. 90.
    Brualla L, Zaragoza FJ, Sauerwein W. Monte Carlo simulation of the treatment of eye tumors with (106)Ru plaques: a study on maximum tumor height and eccentric placement. Ocul Oncol Pathol. 2014;1:2–12.Google Scholar
  91. 91.
    Hawkins BS. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin Trials. 2011;8:661–73.Google Scholar
  92. 92.
    Krohn J, Monge OR, Skorpen TN, et al. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation. Eye. 2008;22:1398–403.Google Scholar
  93. 93.
    Shields CL, Naseripour M, Cater J, et al. Plaque radiotherapy for large posterior uveal melanomas (≥8-mm thick) in 354 consecutive patients 1. Ophthalmology. 2002;109:1838–49.Google Scholar
  94. 94.
    Rouberol F, Roy P, Kodjikian L, et al. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Am J Ophthalmol. 2004;137:893–900.Google Scholar
  95. 95.
    Anteby II, Pe’er J. Need for confirmation of positioning of ruthenium plaques by postoperative B-scan ultrasonography. Ophthalmic Surg Lasers. 1996;27(12):1024–9.Google Scholar
  96. 96.
    Aziz HA, Al Zahrani YA, Bena J, et al. Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation. Br J Ophthalmol. 2017;101(6):747–51.Google Scholar
  97. 97.
    Chang MY, Kamrava M, Demanes DJ, et al. Intraoperative ultrasonography-guided positioning of iodine 125 plaque brachytherapy in the treatment of choroidal melanoma. Ophthalmology. 2012;119(5):1073–7.Google Scholar
  98. 98.
    Tabandeh H, Chaudhry NA, Murray TG, et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129(2):199–204.Google Scholar
  99. 99.
    Design and methods of a clinical trial for a rare condition: The collaborative ocular melanoma study. Control Clin Trials. 1993;14:362–391.Google Scholar
  100. 100.
    Perez BA, Mettu P, Vajzovic L, et al. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. Int J Radiat Oncol Biol Phys. 2014;89:127–36.Google Scholar
  101. 101.
    Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22:209–34.Google Scholar
  102. 102.
    Wang Z, Nabhan M, Schild SE, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:18–26.Google Scholar
  103. 103.
    Dieckmann K, Georg D, Zehetmayer M, et al. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol. 2003;67:199–206.Google Scholar
  104. 104.
    Langmann G, Pendl G, Klaus-Müllner, et al. Gamma knife radiosurgery for uveal melanomas: an 8-year experience. J Neurosurg. 2000;93:184–8.Google Scholar
  105. 105.
    Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118:773–8.Google Scholar
  106. 106.
    Langmann G, Pendl G, Müllner K, et al. High-compared with low-dose radiosurgery for uveal melanomas. J Neurosurg. 2002;97:640–3.Google Scholar
  107. 107.
    Astrahan MA, Luxton G, Pu Q, et al. Conformal episcleral plaque therapy. Int J Radiat Oncol Biol Phys. 1997;39:505–19.Google Scholar
  108. 108.
    American Brachytherapy Society – Ophthalmic Oncology Task Force. Electronic address pec, Committee AO. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.Google Scholar
  109. 109.
    Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol. 2016;28:e17–27.Google Scholar
  110. 110.
    Mishra KK, Quivey JM, Daftari IK, et al. Long-term results of the UCSF-LBNL randomized trial: charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma. Int J Radiat Oncol Biol Phys. 2015;92:376–83.Google Scholar
  111. 111.
    Char DH, Quivey JM, Castro JR, et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. Ophthalmology. 1993;100:1547–54.Google Scholar
  112. 112.
    Berry JL, Dandapani SV, Stevanovic M, et al. Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol. 2013;131:1435–42.Google Scholar
  113. 113.
    Bogner J, Petersch B, Georg D, et al. A noninvasive eye fixation and computer-aided eye monitoring system for linear accelerator-based stereotactic radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;56:1128–36.Google Scholar
  114. 114.
    Furdova A, Strmen P, Waczulikova I, et al. One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma. Eur J Ophthalmol. 2011;22:226–35.Google Scholar
  115. 115.
    Petersch B, Bogner J, Dieckmann K, et al. Automatic real-time surveillance of eye position and gating for stereotactic radiotherapy of uveal melanoma. Med Phys. 2004;31:3521–7.Google Scholar
  116. 116.
    Sarici AM, Pazarli H. Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2013;251:285–94.Google Scholar
  117. 117.
    Wen JC, Oliver SC, Mccannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye. 2009;23:1254–68.Google Scholar
  118. 118.
    Puusaari I, Heikkonen J, Kivelä T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology. 2004;111:1768–77.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Richard L. S. Jennelle
    • 1
    Email author
  • Jesse L. Berry
    • 1
    • 2
  • Jonathan W. Kim
    • 1
  1. 1.Children’s Hospital Los AngelesKeck School of MedicineLos AngelesUSA
  2. 2.USC Roski Eye InstituteKeck School of Medicine of USCLos AngelesUSA

Personalised recommendations